NCT05777031 - Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

January 15, 2026

Study Completion Date

January 15, 2026

Conditions

Peyronie DiseaseSexual Dysfunctions, PsychologicalGenital Diseases, Male

Interventions

DRUG

Collagenase Clostridium Histolyticum (CCH)

Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.

Trial Locations (2)

33136

RECRUITING

University of Miami - Desai Sethi Urology Institute, Miami

RECRUITING

University of Miami, Miami